Source comparison
BPC-157 vs PRP Therapy: Head-to-Head Comparison
Primary Mechanism VEGF receptor upregulation → angiogenesis and fibroblast proliferation Autologous growth factor delivery (PDGF, TGF-β, IGF-1) → collagen synthesis and tissue remodeling BPC-157 works systemically; PRP acts locally at injection site Administra
This comparison does not assign a generated winner or score.
- Primary Mechanism
- VEGF receptor upregulation → angiogenesis and fibroblast proliferation
- Autologous growth factor delivery (PDGF, TGF-β, IGF-1) → collagen synthesis and tissue remodeling
- BPC-157 works systemically; PRP acts locally at injection site
- Administration Route
- Subcutaneous self-injection (daily, 250–500mcg)
- In-office ultrasound-guided injection into target tissue (single or 2–3 sessions spaced 4–6 weeks)
- BPC-157 allows home administration; PRP requires clinical visit
- Onset of Effect
- 7–14 days for subjective pain reduction; 4–6 weeks for structural changes on imaging
- 2–4 weeks for pain reduction; 8–12 weeks for functional improvement
- Both require weeks to months. Neither is an acute pain reliever
- Treatment Duration
- 4–8 weeks continuous daily injection for acute injuries; 8–12 weeks for chronic tendinopathy
- 1–3 injections over 3–6 months; effects plateau at 6 months
- BPC-157 requires daily compliance; PRP is episodic
- Cost (Per Course)
- $80–150/month for peptide (excludes syringes, bacteriostatic water)
- $500–2,000 per injection session (includes blood draw, processing, imaging guidance)
- BPC-157 is lower total cost for courses >3 months
- Regulatory Status
- Not FDA-approved; legal for research use only
- Autologous biologic. No FDA approval required for off-label use
- PRP has broader clinical acceptance despite similar evidence gaps